title: Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
abstract: Revised guidelines for the staging and response criteria of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) were recently published to include the expanding role of positron emission tomography/computed tomography (PET/CT) using (18)F-fluoro-2-deoxyglucose. Here, we discuss the new guidelines and the need for standardized PET acquisition and interpretation in HL and NHL. We also discuss how the role for CT is evolving in the process of making treatment decisions and provide insight on how best to standardize the use of PET/CT for making therapeutic choices.
authors.affiliation: Vanderbilt University Medical Center, Nashville, Tennessee, USA.
authors.forename: Dominique
authors.initials: D
authors.lastname: Delbeke
authors.forename: Sigrid
authors.initials: S
authors.lastname: Stroobants
authors.forename: Eric
authors.initials: E
authors.lastname: de Kerviler
authors.forename: Christian
authors.initials: C
authors.lastname: Gisselbrecht
authors.forename: Michel
authors.initials: M
authors.lastname: Meignan
authors.forename: Peter S
authors.initials: PS
authors.lastname: Conti
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging* / Q000188:drug therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D017410:Practice Guidelines as Topic; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18